ERS Assembly Lifetime Achievement Awards
Assembly 2: Professor Nicolino Ambrosino
|Professor Ambrosino (FERS) is a Research Consultant at the Istituti Clinici Maugeri, Pavia, Italy, and Universitas Sebelas Maret, Surakarta, Indonesia.
He has been: Research and Clinical Department Director at Auxilium Vitae, Volterra; Director of the Respiratory Unit, University Hospital, Pisa; Primary pulmonologist, Pulmonary Division, S. Maugeri Foundation, Gussago, Italy; and appointed Professor at Italian Universities.
He has been involved in ERS in educational, scientific, institutional and editorial aspects. He has held the positions of: Education Programme Director; Secretary of the ERS Clinical Assembly; and Head of Pulmonary Rehabilitation Working Group.
He has been a Chief Editor of the European Respiratory Topics, Co-Editor of Breathe, and Associate Editor of European Respiratory Journal, as well as Co-Chair of the ERS Task Force on telemonitoring in ventilator-dependent patients.
He won the ERS Educational Award in 2013 and 2015, and the ATS Pulmonary Rehabilitation Assembly Award in 2015.
His research activity has been devoted to COPD, respiratory critical care, pulmonary rehabilitation and home respiratory care. He contributed to the development of non-invasive mechanical ventilation in acute and chronic respiratory failure with several clinical trials and original experimental studies. Results have been published in more than 250 cited articles (H index: 48, Scopus) with more than 9000 citations.
Assembly 3: Professor Terry Tetley
|Terry Tetley is Professor of Lung Cell Biology at Imperial College London. She heads the Lung Cell Biology Group in the Division of Airways Disease at the National Heart and Lung Institute.
Her research focuses on mechanisms of pulmonary inflammation and lung disease due to inhalation of airborne toxicants, including ambient particulate air pollution, cigarette smoke, engineered nanoparticles (therapeutic and accidental exposure) and microbial material. She is also interested in nanodrug delivery via inhalation to treat lung and cardiovascular disease.
Her group has established novel in vitro human lung cell models of the blood-gas barrier for mechanistic studies to inform in vivo and translational studies.
She enjoys her multidisciplinary research, which involves collaborations with basic and clinical respiratory scientists, material scientists, chemists, engineers and bioengineers. This research has attracted funding from UK government agencies, the EU and the USA.
Professor Tetley also teaches undergraduate and post graduate students. She is a College Consul, a past President of the British Society for Lung Research, and has had a number of roles within the European Respiratory Society. She is a Fellow of the Royal Society of Biology (UK) and proud to be a Fellow of the European Respiratory Society.
Assembly 5: Dr Pascal Chanez
|Dr Pascal Chanez MD, PhD, FERS is a consultant and full Professor of Respiratory Medicine attending the Clinique des bronches, de l'allergie et du sommeil at the APHM and Aix Marseille University in Marseille, France. He coordinates a research group at INSERM in the same institute on the role of bronchial epithelium in inflammation and environmental aggression in severe bronchial diseases (CV2N center).
He is the head of a clinical research group investigating new innovative treatments for severe asthma and COPD. He gained his MD and PhD from the University of Montpellier and was a fellow at the Imperial College in London, UK with Professor P. J. Barnes.
He is author or co-author of more than 300 peer reviewed articles, reviews and monographs (H-index (Web of Science): 61: see pubmed n=418). He was an editor of the European Respiratory Journal and is on the editorial board of the Journal of Allergy and Clinical Immunology. He was also the head of the LRPC of Assembly 5.
His clinical and research interests are devoted to a better understanding of the mechanisms of severe asthma and COPD with a special effort put into bringing clinical and biological findings together to provide patients with new specific biomarkers and therapies.